RG

Robin Gao

Principal at Sixty Degree Capital

Canada

Overview

Work Experience

SD

Sixty Degree Capital

  • Principal

    2022 - Current

    Biotech / Healthcare venture investment. Exits: Schrödinger, Monte Rosa, Cincor Pharma, Arcellx, Northern Biologics, Engage Therapeutics, Turnstone Biologics, Korro Bio, Contineum Therapeutics.

  • Associate

    2019 - 2022

FH

Focal Healthcare

  • Corporate Development

    2018 - 2019

    Focal Healthcare is a medical device company developing MRI/TRUS Fusion targeted guidance system for prostate cancer biopsy and therapy.

A

AmacaThera

  • Business Development

    2018 - 2018

    AmacaThera is a biotech company developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

AI

Apotex Inc.

  • Pre-Clinical Discovery

    2016 - 2016

    Preclinical ADMET studies to screen neurodegenerative disease drug candidates.

Uo

University of Toronto

  • Teaching Assistant

    2016 - 2016

    CHMC42 Organic Synthesis with laboratory component

  • Undergraduate Thesis Student

    2015 - 2016

    Novel MRI contrast agent

Uo

University of Toronto

  • Research Assistant

    2014 - 2014

    HIV vaccine

Education

Relevant Websites